Therapeutic statusb | |||||
---|---|---|---|---|---|
Clinical statusa | Intermittent | Mild | Moderate | Severe | Total (%) |
Intermittent | 47c | 11d | 10e | 0f | 68 (31) |
Mild persistent | 6d | 2e | 12f | 0f | 20 (9) |
Moderate persistent | 7e | 5f | 11f | 1f | 24 (11) |
Severe persistent | 20f | 20f | 65f | 2f | 107 (49) |
Total (%) | 80 (37) | 38 (17) | 98 (45) | 3 (1) | 219 (100) |
↵aClinical classification: severe/persistent (step 4): daily use of ß2 agonists OR dyspnoea within exacerbations OR nocturnal asthma every night OR physical activities limited by asthma OR peak expiratory flow (PEF) rate<60% of predicted; moderate persistent (step 3): daily asthma symptoms OR nocturnal asthma >once a week but <every night OR PEF rate range 60–80% of predicted or its variability>30%; mild persistent (step 2): asthma symptoms once a week but <once a day OR night time asthma >2 × month but ≤ once a week OR PEF >80% of predicted but its varia-bility 20–30%; intermittent (step 1): asthma symptoms < once a week AND night time asthma <2 × month AND no physical activities limitation AND PEF >80% of predicted AND its variability<20%.
↵bTreatment classification: severe persistent (step 4): oral corticosteroid whatever the associated treatment could be; moderate persistent (step 3): inhaled corticosteroid AND long acting inhaled ß2 agonist and/or long acting theophylline and/or oral ß2 agonist and/or leukotriene inhibitor; mild persistent (step 2): cromone and/or long acting theophylline and/or inhaled long acting ß2 agonist without inhaled corticosteroid OR inhaled corticosteroid alone; intermittent (step 1): no current asthma medications.
c,d,e,fFinal GINA classifications:
↵cintermittent
↵dmild
↵emoderate
↵fsevere.